The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression

Journal of Cellular Biochemistry

Volumn 99, Issue 2, 2006, Pages 345-361

  Knudsen, Beatrice S ^a   Miranti, Cindy K ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Androgen receptor; Growth factor receptors; Integrins; Prostate cancer; Signal transduction

Indexed keywords

ANDROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; INTEGRIN;

CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CANCER TISSUE; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; DRUG TARGETING; HUMAN; METASTASIS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SECRETORY CELL; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INTEGRINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE; PROSTATIC NEOPLASMS; RECEPTOR CROSS-TALK; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33748951893     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20934     Document Type: Review

References (125)

1. Alt A, Ohba M, Li L, Gartsbein M, Belanger A, Denning MF, Kuroki T, Yuspa SH, Tennenbaum T. 2001. Protein Kinase Cδ-mediated phosphorylation of α6β4 is associated with reduced integrin localization to the hemidesmosome and decreased keratinocyte attachment. Cancer Res 61:4591-4598.
2. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T, Harper W. 2004. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10:6572-6578.
3. Bass R, Werner F, Odintsova E, Sugiura T, Berditchevski F, Ellis V. 2005. Regulation of urokinase receptor proteolytic function by the tetraspanin CD82. J Biol Chem 280:14811-14818.
4. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC. 2004. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 64:8867-8875.
5. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. 2004. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851.
6. Bill HM, Knudsen B, Moores SL, Muthuswamy SK, Rao VR, Brugge JS, Miranti CK. 2004. Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol Cell Biol 24:8586-8599.
7. Bisanz K, Yu J, Edlund M, Spohn B, Hung MC, Chung LW, Hsieh CL. 2005. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 12:634-643.
8. Blasi F, Carmeliet P. 2002. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932-943.
9. Bonaccorsi L, Carloni V, Muratori M, Salvadori A, Giannini A, Carini M, Serio M, Forti G, Baldi E. 2000. Androgen receptor expression in prostate carcinoma cells suppresses α6β4 integrin-mediated invasive phenotype. Endocrinology 141:3172-3182.
10. Bonkhoff H. 1996. Role of the basal cells in premalignant changes of the human prostate: A stem cell concept for the development of prostate cancer. Eur Urol 30:201-205.
11. Cabodi S, Moro L, Bergatto E, Boeri Erba E, Di Stefano P, Turco E, Tarone G, Defilippi P. 2004. Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem Soc Trans 32:438-442.
12. Carson JP, Kulik G, Weber MJ. 1999. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B. Cancer Res 59:1449-1453.
13. Catz SD, Johnson JL. 2003. BCL-2 in prostate cancer: A minireview. Apoptosis 8:29-37.
14. Chatterjee B. 2003. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem 253:89-101.
15. Chen J, Diacovo TG, Grenache DG, Santoro SA, Zutter MM. 2002. The α2 integrin subunit-deficient mouse: A multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am J Pathol 161:337-344.
16. Chi KN, Gleave ME. 2004. Antisense approaches in prostate cancer. Expert Opin Biol Ther 4:927-936.
17. Clemmons DR, Maile LA. 2005. Interaction between insulin-like growth factor-I receptor and αvβ3 integrin linked signaling pathways: Cellular responses to changes in multiple signaling inputs. Mol Endocrinol 19:1-11.
18. Cooper CR, Chay CH, Pienta KJ. 2002. The role of αvβ3 in prostate cancer progression. Neoplasia 4:191-194.
19. Cress AE, Rabinovitz I, Zhu W, Nagle RB. 1995. The α6β1 and α6β4 integrins in human prostate cancer progression. Cancer Metastasis Rev 14:219-228.
20. Culig Z, Klocker H, Bartsch G, Hobisch A. 2002. Androgen receptors in prostate cancer. Endocr Relat Cancer 9:155-170.
21. Culig Z, Steiner H, Bartsch G, Hobisch A. 2005. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr Relat Cancer 12:229-244.
22. Davis TL, Cress AE, Dalkin BL, Nagle RB. 2001. Unique expression pattern of the α6β4 integrin and laminin-5 in human prostate carcinoma. Prostate 46:240-248.
23. Demetriou MC, Pennington ME, Nagle RB, Cress AE. 2004. Extracellular α6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp Cell Res 294:550-558.
24. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. 2001. Delineation of prognostic biomarkers in prostate cancer. Nature 412:822-826.
25. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. 2001. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27:222-224.
26. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, Moats S, Ramirez A, Jorcano J, Conti C. 2000. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 97:3455-3460.
27. DiPersio CM, van der Neut R, Georges-Labouesse E, Kreidberg JA, Sonnenberg A, Hynes RO. 2000. α3β1 and α6β4 integrin receptors for laminin-5 are not essential for epidermal morphogenesis and homeostasis during skin development. J Cell Sci 113:3051-3062.
28. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT. 1996. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 56:4387-4390.
29. Donjacour AA, Thomson AA, Cunha GR. 2003. FGF-10 plays an essential role in the growth of the fetal prostate. Dev Biol 261:39-54.
30. Edlund M, Miyamoto T, Sikes RA, Ogle R, Laurie GW, Farach-Carson MC, Otey CA, Zhau HE, Chung LWK. 2001. Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 12:99-107.
31. Evangelou A, Letarte M, Marks A, Brown TJ. 2002. Androgen modulation of adhesion and antiadhesion molecules in PC-3 prostate cancer cells expressing androgen receptor. Endocrinology 143:3897-3904.
32. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
33. Fornaro M, Steger CA, Bennett AM, Wu JJ, Languino LR. 2000. Differential role of β1C and β1A integrin cytoplasmic variants in modulating focal adhesion kinase, protein kinase B/AKT, and Ras/Mitogen-activated protein kinase pathways. Mol Biol Cell 11:2235-2249.
34. Fornaro M, Manes T, Languino LR. 2001. Integrins and prostate cancer metastases. Cancer Metastasis Rev 20: 321-331.
35. Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M, Altieri DC, Languino LR. 2003. Fibronectin protects prostate cancer cells from tumor necrosis factor-α-induced apoptosis via the AKT/survivin pathway. J Biol Chem 278:50402-50411.
36. Foster BA, Evangelou A, Gingrich JR, Kaplan PJ, DeMayo F, Greenberg NM. 2002. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation 70:624-632.
37. Frisch SM, Screaton RA. 2001. Anoikis mechanisms. Curr Opin Cell Biol 13:555-562.
38. Fry PM, Hudson DL, O'Hare MJ, Masters JR. 2000. Comparison of marker protein expression in benign prostatic hyperplasia in vivo and in vitro. BJU Int 85:504-513.
39. Gandarillas A, Watt FM. 1997. c-Myc promotes differentiation of human epidermal stem cells. Genes Dev 11:2869-2882.
40. Gebhardt A, Frye M, Herold S, Benitah SA, Braun K, Samans B, Watt FM, Elsasser H-P, Eilers M. 2006. Myc regulates keratinocyte adhesion and differentiation via complex formation with Miz1 10.1083/jcb.200506057. J Cell Biol 172:139-149.
41. Gelinas C, White E. 2005. BH3-only proteins in control: Specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev 19:1263-1268.
42. Ghosh PM, Malik S, Bedolla R, Kreisberg JI. 2003. Akt in prostate cancer: Possible role in androgen-independence. Curr Drug Metab 4:487-496.
43. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ. 1999. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59:279-284.
44. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ. 2002. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277:29304-29314.
45. Gleave M, Miyake H, Chi K. 2005. Beyond simple castration: Targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol 56(Suppl 1):47-57.
46. Gmyrek GA, Walburg M, Webb CP, Yu HM, You X, Vaughan ED, Vande Woude GF, Knudsen BS. 2001. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 159:579-590.
47. Goel HL, Breen M, Zhang J, Das I, Aznavoorian-Cheshire S, Greenberg NM, Elgavish A, Languino LR. 2005. β1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res 65:6692-6700.
48. Greer EL, Brunei A. 2005. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24:7410-7425.
49. Grossmann ME, Huang H, Tindall DJ. 2001. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687-1697.
50. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, Tilley W, Greenberg NM. 2005. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 102:1151-1156.
51. Heinlein CA, Chang C. 2004. Androgen receptor in prostate cancer. Endocr Rev 25:276-308.
52. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. 1997. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 126:59-73.
53. Hermanto U, Zong CS, Li W, Wang LH. 2002. RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol Cell Biol 22:2345-2365.
54. Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. 2005. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J 390:125-136.
55. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ. 2001. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 276:38830-38836.
56. Huang H, Muddiman DC, Tindall DJ. 2004a. Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. J Biol Chem 279:13866-13877.
57. Huang H, Zegarra-Moro OL, Benson D, Tindall DJ. 2004b. Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells. Oncogene 23:2161-2176.
58. Ing NH. 2005. Steroid hormones regulate gene expression posttranscriptionally by altering the stabilities of messenger RNAs. Biol Reprod 72:1290-1296.
59. Jackson P, Ow K, Yardley G, Delprado W, Quinn DI, Yang JL, Russell PJ. 2003. Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpression. Prostate Cancer Prostatic Dis 6:174-181.
60. Jia Y, Ransom RF, Shibanuma M, Liu C, Welsh MJ, Smoyer WE. 2001. Identification and characterization of hic-5/ARA55 as an hsp27 binding protein. J Biol Chem 276:39911-39918.
61. Kirchhofer D, Peek M, Lipari MT, Billed K, Fan B, Moran P. 2005. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 579:1945-1950.
62. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. 2004. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6:185-195.
63. Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL, Nagle RB. 1994. Differential expression of extracellular matrix molecules and the α6-integrins in the normal and neoplastic prostate. Am J Pathol 145: 167-174.
64. Knudsen BS, Edlund M. 2004. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 91: 31-67.
65. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL, Vande Woude GF. 2002. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60:1113-1117.
66. Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE. 2005. Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol 167: 255-266.
67. Kostenuik PJ, Singh G, Orr FW. 1997. Transforming growth factor beta upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. Clin Exp Metastasis 15:41-52.
68. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. 1996. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576.
69. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM. 2004. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232-5236.
70. Lang SH, Sharrard RM, Stark M, Villette JM, Maitland NJ. 2001. Prostate epithelial cell lines form spheroids with evidence of glandular differentiation in three-dimensional Matrigel cultures. Br J Cancer 85:590-599.
71. Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W. 2003. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 23:104-118.
72. Liao X, Tang S, Thrasher JB, Griebling TL, Li B. 2005. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 4:505-515.
73. Lin J, Adam RM, Santiestevan E, Freeman MR. 1999. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 59:2891-2897.
74. Lynch RL, Konicek BW, McNulty AM, Hanna KR, Lewis JE, Neubauer BL, Graff JR. 2005. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res 3:163-169.
75. Maecker HT, Todd SC, Levy S. 1997. The tetraspanin superfamily: Molecular facilitators. Faseb J 11:428-442.
76. Manohar A, Shome SG, Lamar J, Stirling L, Iyer V, Pumiglia K, DiPersio CM. 2004. Alpha 3 beta 1 integrin promotes keratinocyte cell survival through activation of a MEK/ERK signaling pathway. J Cell Sci 117:4043-4054.
77. Martin DB, Gifford DR, Wright ME, Keller A, Yi E, Goodlett DR, Aebersold R, Nelson PS. 2004. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 64:347-355.
78. McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G. 2005. Phase I trial of a monoclonal antibody specific for alphavbetaS integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 11:7851-7860.
79. Miranti CK, Brugge JS. 2002. Sensing the environment: A historical perspective on integrin signal transduction. Nat Cell Biol 4:E83-E90.
80. Miyake H, Chi KN, Gleave ME. 2000. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6:1655-1663.
81. Moro L, Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L, Tarone G, Defilippi P. 1998. Integrins induce activation of EGF receptor: Role in MAP kinase induction and adhesion-dependent cell survival. Embo J 17:6622-6632.
82. Mulholland DJ, Dedhar S, Wu H, Nelson CC. 2006. PTEN and GSK3β: Key regulators of progression to androgen-independent prostate cancer. Oncogene 25:329-337.
83. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. 2001. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142:4795-4805.
84. Nagakawa O, Akashi T, Hayakawa Y, Junicho A, Koizumi K, Fujiuchi Y, Furuya Y, Matsuda T, Fuse H, Saiki I. 2004. Differential expression of integrin subunits in DU-145/AR prostate cancer cells. Oncol Rep 12:837-841.
85. Nakashiro K, Hara S, Shinohara Y, Oyasu M, Kawamata H, Shintani S, Hamakawa H, Oyasu R. 2004. Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R. Am J Pathol 165: 533-540.
86. Natali PG, Nicotra MR, Botti C, Mottolese M, Bigotti A, Segatto O. 1992. Changes in expression of alpha 6/beta 4 integrin heterodimer in primary and metastatic breast cancer. Br J Cancer 66:318-322.
87. Nemeth JA, Harb JF, Barroso U, Jr., He Z, Grignon DJ, Cher ML. 1999. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 59:1987-1993.
88. Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M. 2003. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 20:413-420.
89. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M, Dickson RB, Lin CY. 2001. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 158:1301-1311.
90. Odintsova E, Voortman J, Gilbert E, Berditchevski F. 2003. Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR. J Cell Sci 116: 4557-4566.
91. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE, Liotta LA. 2001. Reverse phase protein microarrays which capture disease progression show activation of prosurvival pathways at the cancer invasion front. Oncogene 20:1981-1989.
92. Poschl E, Schlotzer-Schrehardt U, Brachvogel B, Saito K, Ninomiya Y, Mayer U. 2004. Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development 10.1242/dev.01037. Development 131:1619-1628.
93. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF. 2001. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 16:125-132.
94. Rabinovitz I, Nagle RB, Cress AE. 1995. Integrin α6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exp Metastasis 13:481-491.
95. Rahman M, Miyamoto H, Chang C. 2004. Androgen receptor coregulators in prostate cancer: Mechanisms and clinical implications. Clin Cancer Res 10:2208-2219.
96. Reddig PJ, Juliano RL. 2005. Clinging to life: Cell to matrix adhesion and cell survival. Cancer Metastasis Rev 24: 425-439.
97. Reuter VE. 1997. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49:16-22.
98. Robinson EJ, Neal DE, Collins AT. 1998. Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate 37:149-160.
99. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE, Cohen MB. 2005. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 24:6773-6784.
100. Ryan MC, Lee K, Miyashita Y, Carter WG. 1999. Targeted disruption of the LAMAS gene in mice reveals abnormalities in survival and late stage differentiation of epithelial cells. J Cell Biol 145:1309-1323.
101. Sharma M, Chuang WW, Sun Z. 2002. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem 277:30935-30941.
102. Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. 2004. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res 64: 7962-7970.
103. Song LN, Gelmann EP. 2005. Interaction of β-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. J Biol Chem 280:37853-37867.
104. Sridhar SC, Miranti CK. 2005. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene Online (online pub ahead of print).
105. Tenniswood MP, Guenette RS, Lakins J, Mooibroek M, Wong P, Welsh JE. 1992. Active cell death in hormone-dependent tissues. Cancer Metastasis Rev 11:197-220.
106. Thomas GV, Horvath S, Smith BL, Crosby K, Lebel LA, Schrage M, Said J, De Kernion J, Reiter RE, Sawyers CL. 2004. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 10:8351-8356.
107. Thomson AA. 2001. Role of androgens and fibroblast growth factors in prostatic development. Reproduction 121:187-195.
108. Uzgare AR, Isaacs JT. 2004. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 64:6190-6199.
109. van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA, De Marzo AM. 2003. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 162: 1529-1537.
110. Verras M, Sun Z. 2005. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett (in press).
111. Walker JL, Zhang L, Zhou J, Woolkalis MJ, Menko AS. 2002. Role for α6 integrin during lens development: Evidence for signaling through IGF-1R and ERK. Dev Dyn 223:273-284.
112. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. 2001. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 153:1023-1034.
113. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H. 2003. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209-221.
114. Ware JL. 1998. Growth factor network disruption in prostate cancer progression. Cancer Metastasis Rev 17:443-447.
115. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. 2001. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292:727-730.
116. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KS, Cress AE. 1993. Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines. J Cancer Res Clin Oncol 119:637-644.
117. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, Plymate SR. 2005a. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 11:3065-3074.
118. Wu R-C, Smith CL, O'Malley BW. 2005b. Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr Rev 26:393-399.
119. Yanez-Mo M, Mittelbrunn M, Sanchez-Madrid F. 2001. Tetraspanins and intercellular interactions. Microcirculation 8:153-168.
120. Yang C-C, Lin H-P, Chen C-S, Yang Y-T, Tseng P-H, Rangnekar VM, Chen C-S. 2003. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J Biol Chem 278:25872-25878.
121. Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E, Chen YT, Hu YC, Wang L, Chuang KH, Wu CT, Chang C. 2005. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 280:33558-33565.
122. Yu HM, Frank DE, Zhang J, You X, Carter WG, Knudsen BS. 2004. Basal prostate epithelial cells stimulate the migration of prostate cancer cells. Mol Carcinog 41: 85-97.
123. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. 2002. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013.
124. Zhang Z, Vuori K, Reed JC, Ruoslahti E. 1995. The α5β1integrin supports survival of cells on fibronectin and upregulates Bcl-2 expression. Proc Natl Acad Sci USA 92: 6161-6165.
125. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. 1999. Prostatic carcinoma cell migration via αvβ3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59:1655-1664.